特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

遺伝子治療市場 - R&Dと収益予測:2020年~2030年

Gene Therapy R&D and Revenue Forecasts 2020-2030: Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Others

発行 Visiongain Ltd 商品コード 935835
出版日 ページ情報 英文 215 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=138.90円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

遺伝子治療市場 - R&Dと収益予測:2020年~2030年 Gene Therapy R&D and Revenue Forecasts 2020-2030: Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Others
出版日: 2020年03月06日 ページ情報: 英文 215 Pages
概要

遺伝子治療市場は、予測期間の前半にCAGRで32%の成長が予測されています。

当レポートでは、世界の遺伝子治療市場について調査分析し、市場概要、市場力学、市場予測、主要企業などについて、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 遺伝子治療のイントロダクション

  • 遺伝子治療とは
  • 遺伝子治療の種類
  • 調査から除外された製品
  • 遺伝子治療ベクター

第3章 遺伝子治療の世界市場:主要な治療法と予測

  • 遺伝子治療の世界市場:製品の概要
  • Luxturna
  • Kymriah
  • Yescarta
  • Zolgensma
  • Gendicine (rAd-p53)
  • Oncorine
  • Neovasculgen
  • Strimvelis
  • Glybera

第4章 遺伝子療法の世界市場:ベクター別、予測

  • ウイルスベクター
  • 非ウイルスベクター

第5章 遺伝子治療の世界市場と疾患サブマーケット

  • 遺伝子治療の世界市場
  • 遺伝子治療市場の予測
  • がんの遺伝子治療
  • 希少疾患の遺伝子治療
  • 心血管疾患の遺伝子治療
  • 眼科疾患の遺伝子治療
  • 感染症の遺伝子治療
  • 神経疾患の遺伝子治療
  • 糖尿病の遺伝子治療
  • その他の疾患の遺伝子治療

第6章 遺伝子療法の世界市場:地域別、予測

  • 遺伝子治療の主要地域市場
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第7章 R&Dのパイプライン分析と予測

第8章 遺伝子治療市場に関心のある企業:堅牢なパイプラインが将来の収益を生む

第9章 調査インタビュー

第10章 遺伝子治療市場の定性分析

第11章 結論

図表

List of Tables:

  • Table 3.1 Approved Gene Therapies, 2019
  • Table 3.2 Luxturna Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 3.3 Kymriah Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 3.4 Yescarta Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 3.5 Zolgensma Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 3.6 Gendicine Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 3.7 Gene Therapies in Pipeline, 2019
  • Table 3.8 Oncorine Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 3.9 Neovasculgen Historical Revenue Comparisons, Revenue ($m), AGR (%), 2014-2018
  • Table 3.10 Neovasculgen Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 3.11 Strimvelis Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.1 Viral Vector Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.2 Retroviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.3 Lentiviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.4 Adenoviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.5 Adeno Associated Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.6 Herpes Simplex Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.7 Poxvirus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.8 Vaccinia Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.9 Non-Viral Vector Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.10 Naked/Plasmid Vectors Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.11 Gene Gun Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.12 Electroporation Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.13 Lipofection Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 5.1 Leading Gene Therapy Drugs by Revenue ($bn), 2019
  • Table 5.2 World Market Forecasts for Gene Therapy Drugs by Indication, Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2019-2030
  • Table 5.3 Selected Anti-Angiogenic Gene Therapy Using a Non-Viral Vector, 2019
  • Table 5.4 Selected Anti-Angiogenic Gene Therapy Using a Retroviral Vector, 2019
  • Table 5.5 Selected Anti-Angiogenic Gene Therapy Using an Adenoviral Vector, 2019
  • Table 5.6 Selected Anti-Angiogenic Gene Therapy Using an Adeno-Associated Virus Vector, 2019
  • Table 5.7 Selected Anti-Angiogenic Gene Therapy Using Lentiviral Vector, 2019
  • Table 5.8 Global Gene Therapy Clinical Trials by Indication, 2019
  • Table 5.9 Selected Cancer Gene Therapies in Phase 2 and Phase 3 Clinical Trial Development, 2019
  • Table 5.10 Selected Cancer Gene Therapies in Phase 1 and Phase 1/2 Clinical Trial Development, 2019
  • Table 5.11 Global Gene Therapy Market: Revenue ($bn) and Market Shares (%) by Indication, 2019
  • Table 5.12 Global Market Forecast for Cancer Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
  • Table 5.13 Rare Diseases Gene Therapy Pipeline, 2019
  • Table 5.14 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
  • Table 5.15 Cardiovascular Gene Therapy Pipeline, 2019
  • Table 5.16 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
  • Table 5.17 Preclinical Ophthalmologic Pipeline, 2019
  • Table 5.18 Clinical Ophthalmologic Pipeline, 2019
  • Table 5.19 Additional Products in the Clinical Ophthalmologic Pipeline, 2019
  • Table 5.20 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
  • Table 5.21 Preclinical Infectious Diseases Pipeline, 2019
  • Table 5.22 Global Infectious Diseases Market Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
  • Table 5.23 Preclinical Neurological Disorders Pipeline, 2019
  • Table 5.24 Global Neurological Disorders Market Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
  • Table 5.25 Preclinical Diabetes Mellitus Pipeline, 2019
  • Table 5.26 Global Diabetes Mellitus Market Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
  • Table 5.27 Global Market Forecast for Other Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
  • Table 5.28 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2020-2025
  • Table 5.29 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2025-20230
  • Table 6.1 World Gene Therapy Market, by Region: Revenue ($Bn) and Market Share (%) 2019 and 2030
  • Table 6.2 Global Gene Therapy Market Forecast, by Region: Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 6.3 North America Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 6.4 Europe Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 6.5 Asia Pacific Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 6.6 Latin America Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 6.7 MEA Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 7.1 Promising Gene Therapies in Development, 2019
  • Table 7.2 Gene Therapies in Phase 3, 2019
  • Table 7.3 Collatagene Forecast, Revenue ($mn), AGR (%), CAGR (%), 2019-2030
  • Table 7.4 BC-819 Forecast, Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 7.5 Lenti-D Forecast, Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 8.1 UniQure B. V.: Overview, 2020
  • Table 8.2 uniQure Pipeline, 2020
  • Table 8.3 Biogen: Overview, 2020
  • Table 8.4 Bluebird Bio: Overview, 2020
  • Table 8.5 Spark Therapeutics: Overview, 2020
  • Table 8.6 Spark Therapeutics Collaborations, 2020
  • Table 8.7 Applied Genetic Technologies Corporation: Overview, 2020
  • Table 8.8 Oxford Biomedica: Overview, 2020
  • Table 8.9 Gensight Biologics: Overview, 2020
  • Table 8.10 Celgene Corporation: Overview, 2020
  • Table 8.11 GlaxoSmithKline plc: Overview, 2020
  • Table 8.12 Takeda Pharmaceuticals: Overview, 2019
  • Table 8.13 Cellectis: Overview, 2020
  • Table 8.14 Sangamo Therapeutics, Inc.: Overview, 2020
  • Table 8.15 REGENXBIO Inc.: Overview, 2020
  • Table 8.16 Voyager Therapeutics: Overview, 2020
  • Table 8.17 Bristol-Myers Squibb Company: Overview, 2020
  • Table 8.18 Genzyme Corporation: Overview, 2020
  • Table 8.19 Chiesi Farmaceutici S.p.A: Overview, 2020
  • Table 8.20 Benitec BioPharma: Overview, 2020
  • Table 8.21 Selected Big Pharma Collaborations in Gene Therapy, 2019
  • Table 9.1 Strengths and Weaknesses of the Gene Therapy Drug Treatment Market, 2020
  • Table 9.2 Gene Therapy Pipeline for Neurodegenerative Diseases, 2020
  • Table 9.3 Gene Therapy Pipeline for Metabolic Diseases, 2020
  • Table 9.4 Gene Therapy Pipeline for Musculoskeletal Diseases, 2020
  • Table 9.5 Gene Therapy Pipeline for Viral Diseases, 2020
  • Table 9.6 Opportunities and Threats of the Gene Therapy Drug Market, 2020
  • Table 9.7 Clinical Trials for Standard Drug Development Versus Orphan Drug Development, 2020
  • Table 10.1 World Gene Therapy Market, by Region: Revenue ($Bn) and Market Share (%) 2019 and 2030

List of Figures:

  • Figure 1.1 Global Gene Therapy Market Segmentation Overview, 2020
  • Figure 2.1 Vectors Used in Gene Therapy Clinical Trials, 2019
  • Figure 3.1 Luxturna Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 3.2 Kymriah Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 3.3 Yescarta Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 3.4 Zolgensma Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 3.5 Gendicine Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 3.6 Oncorine Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 3.7 Neovasculgen Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 3.8 Strimvelis Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.1 Viral Vector Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.2 Retroviruses Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.3 Lentiviruses Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.4 Adenoviruses Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.5 Adeno Associated Virus Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.6 Herpes Simplex Virus Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.7 Poxvirus Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.8 Vaccinia Virus Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.9 Non-Viral Vector Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.10 Naked/Plasmid Vectors Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.11 Gene Gun Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.12 Electroporation Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 4.13 Lipofection Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 5.1 Gene Therapy World Market Forecast, Market Size ($bn), AGR (%), 2019-2030
  • Figure 5.2 Global Gene Therapy Clinical Trials by Indication, 2019
  • Figure 5.3 Cancer Gene Therapy Pipeline by Phase of Development, 2019
  • Figure 5.4 Global Gene Therapy Market: Market Shares (%) by Indication, 2019
  • Figure 5.5 Global Market Forecast for Cancer Gene Therapies: Revenue ($bn), 2019-2030
  • Figure 5.6 Rare Diseases Gene Therapy Pipeline by Phase of Development, 2020
  • Figure 5.7 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($bn), 2019-2030
  • Figure 5.8 Cardiovascular Gene Therapy Pipeline by Phase of Development, 2019
  • Figure 5.9 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($bn), 2019-2030
  • Figure 5.10 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($bn), 2019-2030
  • Figure 5.11 Global Infectious Diseases Market Forecast: Revenue ($bn), AGR (%), 2019-2030
  • Figure 5.12 Global Neurological Disorders Market Forecast: Revenue ($bn), AGR (%), 2019-2030
  • Figure 5.13 Global Diabetes Mellitus Market Forecast: Revenue ($bn), AGR (%), 2019-2030
  • Figure 5.14 Global Market Forecast for Other Disease Gene Therapies: Revenue ($bn), 2019-2030
  • Figure 5.15 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2025
  • Figure 5.16 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2028
  • Figure 6.1 Global Gene Therapy Market, by Region: Revenues (%), 2019
  • Figure 6.2 Global Gene Therapy Market, by Region: Revenues (%), 2025
  • Figure 6.3 Global Gene Therapy Market, by Region: Revenues (%), 2030
  • Figure 6.4 North America Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 6.5 Europe Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 6.6 Asia Pacific Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 6.7 Latin America Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 6.8 MEA Market Forecast, Revenue ($bn), AGR (%), 2019-2030
  • Figure 7.1 Gene Therapies in Clinical Development by Phase, 2019
  • Figure 7.2 Gene Therapy Market Strategy Analysis Gene Therapy Market Strategy Analysis
  • Figure 7.3 Key Take Ways, Challenges and Application of CRISPR Market
  • Figure 7.4 Impact of CRISPR Technology on the Gene Therapy Market
  • Figure 8.1 Biogen: Revenue ($mn), 2015-2018
  • Figure 8.2 Celgene Corporation: Revenue ($mn), AGR (%), 2014-2018
  • Figure 8.3 Celgene Corporation: Regional Segment Revenue Share (%), 2018
  • Figure 8.4 GlaxoSmithKline plc: Revenue ($mn), 2014-2018
  • Figure 8.5 GlaxoSmithKline plc: Business Segment Revenue Share (%), 2018
  • Figure 8.6 GlaxoSmithKline plc: Pharmaceutical Business Segment Revenue Share (%),2018
  • Figure 8.7 GlaxoSmithKline plc: by Region Revenue Share (%), 2018
  • Figure 8.8 Takeda Pharmaceuticals: Revenue ($bn), 2016-2018
  • Figure 8.9 Bristol-Myers Squibb Company: Revenue ($bn), AGR (%), 2014-2018
  • Figure 8.10 Bristol-Myers Squibb Company: Regional Segment Revenue Share (%), 2018
  • Figure 10.1 Gene Therapy Drug Treatment Market Forecast by Indication: Market Sizes ($bn), 2019, 2025, and 2030

List of Companies Mentioned

  • 4DMT (4D Molecular Therapeutics)
  • Abeona
  • AGTC (Applied Genetics Technologies Corporation)
  • AMT (Amsterdam Molecular Therapeutics)
  • AnGes MG
  • Asklepios BioPharma
  • AstraZeneca
  • Audentes Therapeutics
  • Avalanche Biotech
  • Bayer Healthcare
  • Beijing Northland Biotech Co
  • Benda Pharmaceutical
  • Benitec Biopharma
  • BioCancell
  • Biogen
  • Biogen Idec
  • Bluebird Bio
  • BMS (Bristol-Myers Squibb)
  • Broad Institute/Whitehead Institute
  • Celgene
  • Cell Therapy Catapult
  • Cellectis
  • Chiesi Farmaceutici
  • Clearside Biomedical
  • Convergence Pharmaceuticals
  • Daiichi Sankyo
  • Dimension Therapeutics
  • Editas Medicine
  • Fondazione Telethon
  • Francis Crick Institute
  • Genable Technologies Ltd
  • Genethon
  • GenSight Biologics
  • GenVec
  • Google
  • GSK (GlaxoSmithKline)
  • Henry Ford Health System
  • HSCI (Human Stem Cells Institute)
  • HSR-TIGET (San Raffaele Telethon Institute for Gene Therapy),
  • ImaginAb
  • Immune Design Corp
  • InoCard
  • Inovio
  • Intellia Therapeutics
  • Invetech
  • Kite Pharma
  • Kolon Group
  • Kolon Life Science
  • Lysogene
  • Mitsubishi Tanabe Pharma Corporation
  • Neuralgene
  • NightstaRx
  • Northwestern Memorial Hospital
  • Novartis
  • OXB (Oxford Biomedica)
  • Pfizer
  • PNP Therapeutics
  • Precision Genome Engineering Inc aka Pregenen
  • ProNai
  • Protek Group
  • Raffaele Hospital
  • REGENX Biosciences
  • Renova Therapeutics
  • Roche
  • Roszdravnadzor
  • Sangamo Biosciences
  • Sanofi
  • Sarepta Therapeutics
  • Shanghai Sunway Biotech
  • Shenzhen SiBiono GeneTech
  • Sotex Pharm Firm
  • Spark Therapeutics
  • SynerGene Therapeutics
  • Takara Bio
  • TAP Biosystems
  • Thermo Fisher Scientific
  • TissueGene
  • ToolGen
  • UC Berkeley
  • UC San Francisco
  • uniQure
  • US Business Innovation Network
  • Vertex Pharmaceuticals
  • Vical Incorporated
  • ViroMed
  • VM Biopharma
  • Voyage Therapeutics

List of Organisation Mentioned

  • ASCO (American Society of Clinical Oncology)
  • ASI (Agency for Strategic Initiatives)
  • CAT (Committee for Advanced Therapies)
  • CBER (Center for Biologics Evaluation and Research)
  • CHMP (Committee for Medicinal Products for Human Use)
  • CHOP (The Children's Hospital of Philadelphia)
  • DCGI (Drugs Controller General of India)
  • DHHS (Department of Health and Human Services)
  • EMA (European Medicines Agency)
  • FDA (US Food and Drug Administration)
  • INSERM (Institut National de la Sante et de la Recherche Medicale)
  • IRB (Institutional Review Boards)
  • MFDS (Korean Ministry of Food and Drug Safety)
  • MHLW (Ministry of Health, Labour, and Welfare)
  • MHRA (Medicines and Healthcare Products Regulatory Agency)
  • Ministry of Health Commission
  • NHS (National Health Service)
  • NICE (the National Institute for Health and Care Excellence)
  • NIH (National Institutes of Health)
  • OHRP (Office for Human Research Protections)
  • PMDA (Pharmaceuticals and Medical Devices Agency)
  • RCGM (Review Committee of Genetic Manipulation)
  • Russian Ministry of Healthcare and Social Development
  • SFDA (State Food and Drug Administration of China)
  • SMC (Scottish Medicines Consortium)
  • The Fund for Promotion of Small Innovative Enterprises in Science and Technology
  • The IGI (Innovative Genomics Initiative)
  • The Innovative Genomics Initiative
  • The Walter and Eliza Hall Institute
  • The Wellcome Trust Sanger Institute
  • WFH (World Federation of Hemophilia)
  • WHO (World Health Organization)
目次
Product Code: PHA0717

The gene therapy market is projected to grow at a CAGR of 32% in the first half of the forecast period. In 2019, the cancer treatment submarket accounted for 55.8% of the gene therapy drug market. Visiongain estimated that gene therapy for rare diseases will be the driver for market growth in the first half of the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 215-page report you will receive 157 charts - all unavailable elsewhere.

The 215-page report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Gene Therapy market forecasts from 2020-2030

This report assesses the approved gene therapy products in the market and gives revenue to 2030.

Provides qualitative analysis and forecast of the submarket by indication for the period 2020-2030:

  • Cancer
  • Cardiovascular disorders
  • Rare diseases
  • Ophthalmological diseases
  • Infectious Diseases
  • Neurological Disorders
  • Diabetes Mellitus
  • Other therapeutic uses

Profiles leading companies that will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include:

  • UniQure
  • Biogen
  • Bluebird Bio
  • Spark Therapeutics
  • Applied Genetics Technologies Corporation
  • Oxford Biomedica
  • GenSight Biologics
  • & Other Companies

Assesses the outlook for the leading gene treatment R&D pipeline for 2019 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, with revenue forecasts for four leading agents :

  • Collategene (AMG0001, AnGes MG/Vical)
  • BC-819 (BioCancell)
  • BC-821 - BioCancell
  • SPK-CHM - Spark Therapeutics
  • SPK-FIX - Spark Therapeutics/Pfizer
  • SPK-TPP1- Spark Therapeutics
  • Lenti-D (Bluebird Bio)
  • LentiGlobin (Bluebird Bio)
  • VM202-DPN - ViroMed

Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2020 to 2030. SWOT analysis is provided and an overview of regulation of the gene therapy market by leading region given.

Our study discusses factors that influence the market including these:

  • Translation of research into marketable products modifying human DNA - gene transfer for therapeutic use, altering the nuclear genome
  • Genomic editing technology and other supporting components
  • Collaborations to develop and launch gene-based products - acquisitions and licensing deals
  • Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
  • Gene therapies for ophthalmologic diseases - next-generation medicines
  • Regulations in the United States, the European Union and Japan - overcoming technological and medical challenges to pass clinical trials.

Visiongain's study is intended for anyone requiring commercial analyses for the gene therapy market. You find data, trends and predictions.

Buy our report today Gene Therapy R&D and Revenue Forecasts 2020-2030: Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Rare Diseases, Cardiovascular Disorders, Ophthalmologic Conditions, Infectious Disease, Neurological Disorders, Diabetes Mellitus.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Gene Therapy Market Overview
  • 1.2 Benefits of This Report
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methods of the Study
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to Gene Therapy

  • 2.1 What is Gene Therapy?
  • 2.2 Types of Gene Therapy
  • 2.3 Products Excluded from the Report
  • 2.4 Gene Therapy Vectors

3. Gene Therapy World Market: Leading Treatments and Forecasts, 2017-2028

  • 3.1 The World Market for Gene Therapy: Overview of Products
  • 3.2 Luxturna
  • 3.3 Kymriah
  • 3.4 Yescarta
  • 3.5 Zolgensma
  • 3.6 Gendicine (rAd-p53) - The First Gene Therapy to Market
  • 3.7 Oncorine: Growth is Hindered by Certain Factors
  • 3.8 Neovasculgen: Russia's First Gene Therapy
  • 3.8.1 Neovasculgen: Historical Performance and Revenue Forecast, 2019-2030
  • 3.9 Strimvelis: Second Gene Therapy for an Inherited Disease Ever to be approved for Sale and the First Corrective Gene Therapy for Children to be Approved Anywhere in the World
  • 3.10 Glybera

4. Gene Therapy World Market: By Vector and Forecasts, 2020-2030

  • 4.1 Viral Vectors
    • 4.1.1 Retroviruses
    • 4.1.2 Lentiviruses
    • 4.1.3 Adenoviruses
    • 4.1.4 Adeno Associated Virus
    • 4.1.5 Herpes Simplex Virus
    • 4.1.6 Poxvirus
    • 4.1.7 Vaccinia Virus
  • 4.2 Non-Viral Vector
    • 4.2.1 Naked/Plasmid Vectors
    • 4.2.2 Gene Gun
    • 4.2.3 Electroporation
    • 4.2.4 Lipofection

5. Gene Therapy World Market and Disease Submarkets, 2019-2030

  • 5.1 The Global Market for Gene Therapy Drug Treatments in 2019
  • 5.2 Gene Therapy Market Forecast, 2019-2030
  • 5.3 Gene Therapy for Cancer
    • 5.3.1 Clinical Trials for Cancer
    • 5.3.2 The Cancer Gene Therapy Treatment Submarket Forecast 2019-2030
  • 5.4 Gene Therapy for Rare Diseases
    • 5.4.1 The Rare Disease Treatment Submarket Forecast 2019-2030
  • 5.5 Gene Therapy for Cardiovascular Diseases
    • 5.5.1 The Cardiovascular Disease Treatment Submarket Forecast 2019-2030
  • 5.6 Gene Therapy for Ophthalmologic Diseases
    • 5.6.1 Advanced Stage Gene Therapies for Ophthalmologic Diseases
    • 5.6.2 The Ophthalmologic Disease Treatment Submarket Forecast 2019-2030
  • 5.7 Gene Therapy for Infectious Diseases
    • 5.7.1 Infectious Diseases Submarket Forecast 2019-2030
  • 5.8 Gene Therapy for Neurological Disorders
    • 5.8.1 Neurological Disorders Submarket Forecast 2019-2030
  • 5.9 Gene Therapy for Diabetes Mellitus
    • 5.9.1 Diabetes Mellitus Submarket Forecast 2019-2030
  • 5.10 Gene Therapy for Other Diseases
    • 5.10.1 The Other Disease Treatment Submarket Forecast 2019-2030
    • 5.10.2 Changing Market Shares: Cancer Disease Gene Therapies Will Dominate and Become Market Leader

6. Gene Therapy World Market: by Region Forecasts, 2020-2030

  • 6.1 Leading Regional Markets of Gene Therapy 2019-2030
  • 6.2 North America
  • 6.3 Europe
  • 6.4 Asia Pacific
  • 6.5 Latin America
  • 6.6 MEA

7. R&D Pipeline Analysis and Forecasts, 2019-2030

  • 7.1 Pipeline
  • 7.2 Pipeline Analysis
  • 7.3 Collategene (AMG0001) - AnGes MG/Vical
  • 7.4 BC-819 - BioCancell
  • 7.5 BC-821 - BioCancell
  • 7.6 Lenti-D - Bluebird Bio
  • 7.7 LentiGlobin (LentiGlobin BB305) - Bluebird Bio
  • 7.8 SPK-CHM - Spark Therapeutics
  • 7.9 SPK-FIX - Spark Therapeutics/Pfizer
  • 7.10 SPK-TPP1- Spark Therapeutics
  • 7.11 VM202-DPN - ViroMed
  • 7.12 Important Pipeline Technology Developments
  • 7.13 Clustered regularly interspaced short palindromic repeats (CRISPR)
  • 7.14 The Future of the Gene Therapy Pipeline

8. Companies of Interest in the Gene Therapy Market: Robust Pipelines Will Yield Revenue in the Future

  • 8.1 UniQure B. V. - the First Commercial Stage Gene Therapy Company in the West
  • 8.2 Biogen - Focusing on Ophthalmologic and Rare Disease Gene Therapies
    • 8.2.1 Biogen: Financial Performance 2015-2018
    • 8.2.2 Biogen: Key News
  • 8.3 Bluebird Bio: Gene Editing Technology
  • 8.4 Spark Therapeutics- Strong Change to Become the First Company with Marketed Gene Therapy in the US
  • 8.5 Applied Genetic Technologies Corporation: Specialisation in Ophthalmologic Diseases
  • 8.6 Oxford Biomedica: Collaboration as a Strategy
  • 8.7 GenSight Biologics - Novel Mitochondrial Technology Platform
  • 8.8 Celgene Corporation
    • 8.8.1 Celgene Corporation: Financial Overview
  • 8.9 GlaxoSmithKline plc.
    • 8.9.1 GlaxoSmithKline plc: Financial Overview
    • 8.9.2 GlaxoSmithKline plc: Recent Transactions Summary
  • 8.10 Takeda Pharmaceuticals
    • 8.10.1 Takeda Pharmaceuticals: Financial Overview
    • 8.10.2 Takeda Pharmaceuticals: Key News
  • 8.11 Cellectis
    • 8.11.1 Cellectis: Key News
  • 8.12 Sangamo Therapeutics, Inc.
    • 8.12.1 Sangamo Therapeutics, Inc: Key News
  • 8.13 REGENXBIO Inc.
    • 8.13.1 REGENXBIO Inc.: Key News
  • 8.14 Voyager Therapeutics
    • 8.14.1 Voyager Therapeutics: Key News
  • 8.15 Bristol Myers Squibb
    • 8.15.1 Bristol-Myers Squibb Company: Financial Overview
    • 8.15.2 Bristol-Myers Squibb Company: Recent Transactions Summary
  • 8.16 Genzyme Corporation
    • 8.16.1 Genzyme Corporation: Key News
  • 8.17 Chiesi Farmaceutici S.p.A
    • 8.17.1 Chiesi Farmaceutici S.p.A: Key News
  • 8.18 Benitec BioPharma
    • 8.18.1 Benitec BioPharma: Key News
  • 8.19 Gene Therapy and Big Pharma: Collaborations

9. Research Interviews

  • 9.1 Kyriacos Mitrophanous, Chief Scientific Officer at Oxford Biomedica
    • 9.1.1 Oxford Biomedica
    • 9.1.2 Gene therapy landscape
    • 9.1.3 Oxford Biomedica LentiVector R
    • 9.1.4 Pricing and Next Steps in Gene Therapy
  • 9.2 Professor Dusko Ilic, Professor of Stem Cell Science, King's College London
    • 9.2.1 Gene therapy landscape
    • 9.2.2 Ethical Considerations with Gene Therapy
    • 9.2.3 Regulation & Pricing of Gene Therapy Products

10. Qualitative Analysis of the Gene Therapy Market, 2020-2030

  • 10.1 SWOT Analysis of the Gene Therapy Treatment Market, 2020
  • 10.2 Strengths: A Vast Pipeline for a Wide Range of Indications
  • 10.3 Weaknesses: Low Patient Populations Cannot Sustain Long-Term Growth
  • 10.4 Opportunities and Threats for the Gene Therapy Drug Market, 2020-2030
  • 10.5 Opportunities: Collaborations and Novel Technologies Will Pave the Way
  • 10.6 Threats: Expensive Drugs with Strict Regulations
  • 10.7 Regional markets: Regulation of the Gene Therapy Market
    • 10.7.1 Gene Therapy Regulations: Evolving with the Market
    • 10.7.2 US Regulations: Strict Regulation of a Cautious Market
    • 10.7.3 EU Regulations: One Approval So Far
    • 10.7.4 Japanese Regulations: A Rigorous Process
    • 10.7.5 China Has Highest Gene Sequencing Capacity

11. Conclusions

  • 11.1 The World Gene Therapy Treatment Market: Current World Outlook
    • 11.1.1 Driver for Growth to 2030: A Vast Pipeline of Gene Therapy Products
    • 11.1.2 Leading Gene Therapy Treatment Submarkets and Products, 2019-2030
    • 11.1.3 Leading Regional Markets and Companies: Partnerships Will Achieve Success
  • 11.2 The Future of the Gene Therapy Treatment Market
    • Associated Visiongain Reports
    • Visiongain Report Sales Order Form
    • About Visiongain
    • Visiongain report evaluation form